Franziska Haderk, PhD
Franziska Haderk, PhD
Postdoctoral scholar
Verified email at ucsf.edu
Title
Cited by
Cited by
Year
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
4732013
Obstacles and opportunities in the functional analysis of extracellular vesicle RNA–an ISEV position paper
B Mateescu, EJK Kowal, BWM van Balkom, S Bartel, SN Bhattacharyya, ...
Journal of extracellular vesicles 6 (1), 1286095, 2017
3072017
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts
J Paggetti, F Haderk, M Seiffert, B Janji, U Distler, W Ammerlaan, YJ Kim, ...
Blood 126 (9), 1106-1117, 2015
2952015
Tumor-derived exosomes modulate PD-L1 expression in monocytes
F Haderk, R Schulz, M Iskar, LL Cid, T Worst, KV Willmund, A Schulz, ...
Science immunology 2 (13), 2017
1162017
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ...
Nature cell biology 20 (9), 1064-1073, 2018
802018
Extracellular vesicles in chronic lymphocytic leukemia
F Haderk, B Hanna, K Richter, M Schnölzer, T Zenz, S Stilgenbauer, ...
Leukemia & lymphoma 54 (8), 1826-1830, 2013
122013
Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer
W Wu, F Haderk, TG Bivona
Cancers 9 (12), 164, 2017
102017
Obstacles and opportunities in the functional analysis of extracellular vesicle RNA-an ISEV position paper. J Extracell Vesicles. 2017; 6: 1286095
B Mateescu, EJ Kowal, BW van Balkom, S Bartel, SN Bhattacharyya, ...
Epub 2017/03/23, 0
7
Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing
A Maynard, CE McCoach, JK Rotow, L Harris, F Haderk, LD Kerr, ...
bioRxiv, 2019
42019
Immunohistochemistry to study YAP in human tissue samples
F Haderk, V Olivas, TG Bivona
The Hippo Pathway, 89-95, 2019
32019
Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss
RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ...
bioRxiv, 188730, 2017
32017
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
A Maynard, CE McCoach, JK Rotow, L Harris, F Haderk, DL Kerr, ...
Cell 182 (5), 1232-1251. e22, 2020
12020
Betacellulin drives therapy resistance in glioblastoma
QW Fan, Z An, RA Wong, X Luo, ED Lu, A Baldwin, MK Mayekar, ...
Neuro-oncology 22 (4), 457-469, 2020
12020
CLL Exosome-derived Y RNA hY4 induces TLR7/8-mediated inflammation and PD-L1 expression in monocytes
F Haderk, L Llao Cid, M Iskar, R Schulz, M Goebel, J Duerig, ...
Blood, The Journal of the American Society of Hematology 128 (22), 3217-3217, 2016
12016
Characterization of Tumor-derived Exosomes and Their Functional Role in the Microenvironment of Chronic Lymphocytic Leukemia
F Haderk
Ruperto-Carola University of Heidelberg, 2016
12016
Chronic Lymphocytic Leukemia-Exosomes Switch Endothelial and Mesenchymal Stromal Cells into Cancer-Associated Fibroblasts to Sustain Leukemic Cell Survival
J Paggetti, F Haderk, M Seiffert, B Janji, YJ Kim, U Diestler, W Ammerlaan, ...
Blood, The Journal of the American Society of Hematology 124 (21), 2927-2927, 2014
12014
Abstract PR11: Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC
F Haderk, D Allegakoen, J Guan, W Wu, T Bivona
Molecular Cancer Research 18 (8 Supplement), PR11-PR11, 2020
2020
B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC
F Haderk, C Fernández-Méndez, KN Shah, W Wu, J Guan, J Rotow, ...
Journal of Thoracic Oncology 15 (2), S27, 2020
2020
A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer
S Kaushik, F Haderk, X Zhao, HM Hu, KN Shah, GM Jang, V Olivas, ...
bioRxiv, 2020
2020
Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF
TG Bivona, R Nichols, F Haderk, C Stahlhut, C Schulze, G Hemmati, ...
Cancer Research 78 (13 Supplement), 3993-3993, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–20